Literature DB >> 8992882

Constitutive expression of non-bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines.

N N Ali1, J Rowe, N M Teich.   

Abstract

Alkaline phosphatase (ALP) plays an important role in bone mineralization; high levels in differentiated osteoblasts allows their identification easily in vitro. It is generally assumed that the activity of ALP in osteosarcoma-derived cell lines commonly used in studies of bone cell biology is exclusively due to the bone/liver/kidney (BLK) isoenzyme. However, we noted that two human osteosarcoma cell lines, U-2 OS and U-393 OS, predominantly expressed a truncated 1.8 kb mRNA for BLK-ALP. This observation stimulated further investigation upon the ability of ALP to form functional protein. We found that, unlike the BLK-ALP of the Saos-2 osteosarcoma cell line, the activity of U-2 OS ALP was thermostable, unaffected by L-homoarginine and levamisole, but inhibited by L-phenylalanine; these properties are characteristic of the placental and/or placental-like (PL-/PL-like ALP) isoenzymes which are 98% homologous at the amino acid level. In the U-393 OS cell line, which expresses the normal-sized 2.5 kb mRNA in substantially higher levels than that produced by U-2 OS cells, the ALP activity had kinetic properties very similar to that produced by the Saos-2 line for all criteria tested. The HOS osteosarcoma cell line (also known as TE-85), which express the normal-sized 2.5 kb BLK-ALP mRNA only, exhibited ALP activity with kinetic properties of both the BLK and PL-/PL-like isoenzymes. The three test lines, U-2 OS, U-393 OS and HOS, produced PL-/PL-like ALP mRNA and protein constitutively, and levels of these increased in cells treated with 1 microM dexamethasone. However, dexamethasone treatment of cells did not alter the types of ALP isoenzyme expressed. Thus our results show that, like Saos-2 cells, U-393 OS cells produce active BLK-ALP exclusively, whereas U-2 OS cells produce PL-/PL-like ALP only, and the HOS cell line produces both. Our findings have important implications for phenotypic characterization of various human osteosarcoma cell lines, and suggest that the production of PL-/PL-like ALP may be a more common occurrence in osteosarcomas than was originally thought.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8992882     DOI: 10.1002/jbmr.5650110412

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Strontium substituted calcium phosphate biphasic ceramics obtained by a powder precipitation method.

Authors:  Hae-Won Kim; Young-Hag Koh; Young-Min Kong; Jun-Gu Kang; Hyoun-Ee Kim
Journal:  J Mater Sci Mater Med       Date:  2004-10       Impact factor: 3.896

2.  The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with esophageal squamous cell carcinoma.

Authors:  Xiao-Li Wei; Dong-Sheng Zhang; Ming-Ming He; Ying Jin; De-Shen Wang; Yi-Xin Zhou; Long Bai; Zhe-Zhen Li; Hui-Yan Luo; Feng-Hua Wang; Rui-Hua Xu
Journal:  Tumour Biol       Date:  2015-09-01

3.  IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.

Authors:  M C Honorati; S Neri; L Cattini; A Facchini
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

4.  Possible prognostic role of IL-17R in osteosarcoma.

Authors:  Maria Cristina Honorati; Luca Cattini; Andrea Facchini
Journal:  J Cancer Res Clin Oncol       Date:  2007-08-10       Impact factor: 4.553

5.  Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Fei Ji; Shun-Jun Fu; Zhi-Yong Guo; Hui Pang; Wei-Qiang Ju; Dong-Ping Wang; Yun-Peng Hua; Xiao-Shun He
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

6.  The Predictive Value of Albumin-to-Alkaline Phosphatase Ratio for Overall Survival of Hepatocellular Carcinoma Patients Treated with Trans-Catheter Arterial Chemoembolization Therapy.

Authors:  Zhan-Hong Chen; Xiao-Ping Zhang; Xiu-Rong Cai; Si-Dong Xie; Meng-Meng Liu; Jin-Xiang Lin; Xiao-Kun Ma; Jie Chen; Qu Lin; Min Dong; Xiang-Yuan Wu; Jing-Yun Wen; Rui-Hua Xu
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.